Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: A multi-institutional, long-term experience

Cancer

Volumn 112, Issue 1, 2008, Pages 75-83

  Perdonà, Sisto ^a   Autorino, Riccardo ^b   Damiano, Rocco ^c   De Sio, Marco ^b   Morrica, Brunello ^a   Gallo, Luigi ^a   Silvestro, Giustino ^a   Farella, Antonio ^d   De Placido, Sabino ^d   Di Lorenzo, Giuseppe ^d  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Bladder cancer; Chemotherapy; Conservative treatment; Radiotherapy; Transurethral resection

Indexed keywords

CISPLATIN; METHOTREXATE; VINBLASTINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER CAPACITY; BLADDER DISEASE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DIARRHEA; DYSURIA; ENTERITIS; FATIGUE; FEMALE; HUMAN; INTESTINE OBSTRUCTION; KIDNEY DYSFUNCTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MUSCLE METASTASIS; NOCTURIA; PRIORITY JOURNAL; PROCTITIS; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINARY FREQUENCY; URINARY URGENCY; UROCYSTITIS; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BLADDER TUMOR; MIDDLE AGED; MULTICENTER STUDY; SURVIVAL; TUMOR RECURRENCE;

ADULT; AGED; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 37449033683     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23137     Document Type: Article

References (28)

1. Stein JP, Skinner DG. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol. 2006;24:296-304.
2. Herr H. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol. 2001;19:89-93.
3. Kuczyk M, Turkeri L, Hammerer P, et al. Is there a role for bladder preserving strategies in the treatment of muscle-invasive bladder cancer? Eur Urol. 2003;44:57-64.
4. Rubin P, Constine LS, Fajardo LF, et al. Overview: Late Effects of Normal Tissue (LENT) scoring system. RTOG Late Effects Working Group. Int J Radiat Oncol Biol Phys. 1995;31:1041-1042.
5. Brown AL, Zietman AI, Shipley WU, et al. An organ preserving approach to muscle-invading transitional cell canter of the bladder. Hematol Oncol Clin North Am. 2004;15:345-358.
6. Housset M, Maulard C, Chretien Y, et al. Combined radiation and chemotherapy for invasive transitional cell carcinoma of the bladder. A prospective study. J Clin Oncol. 1993;11:2150-2157.
7. Sauer R, Birkenhake S, Kuhn R, et al. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys. 1998;40:121-127.
8. Rodel C, Grabenbauer GG, Kuhn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002; 20:3061-3071.
9. Coppin CM, Gospodarowicz MK, James K. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. J Clin Oncol. 1996; 14:2901-2907.
10. Tester W, Porter A, Asbell S, et al. Combined modality program with possible organ preservation for invasive bladder cancer: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys. 1993;25:783-790.
11. Tester W, Caplan R, Heaney J, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol. 1996;14:119-126.
12. Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol. 1998;16:3576-3583.
13. Kaufman DS, Winter KA, Shipley WU, et al. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on initial response. Oncologist. 2000;5:471-476.
14. Hagan MP, Winter KA, Kaufman DS, et al. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys. 2003;57:665-672.
15. Coen JJ, Zietman AL, Kaufman DS, et al. Benchmarks achieved in the delivery of radiation therapy for muscle-invasive bladder cancer. Urol Oncol. 2007;25:76-84.
16. Kachnic LA, Kaufman DS, Heney NM, et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol. 1997;15:1022-1029.
17. Shipley WU, Kaufman DS, Zehr E, et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology. 2002;60:62-68.
18. Arias F, Dominguez MA, Martinez E, et al. Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program. Int J Radiat Oncol Biol Phys. 2000;47:373-378.
19. Danesi DT, Arcangeli G, Cruciani E, et al. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy and hyperfractionated radiotherapy. Cancer. 2004;101:2540-2548.
20. George L, Bladou F, Bardou VJ, et al. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy. Urology. 2004;64: 488-493.
21. Cobo M, Delgado R, Gil S, et al. Conservative treatment with transurethral resection, neoadjuvant chemotherapy followed by radiochemotherapy in stage T2-3 transitional bladder cancer. Clin Transl Oncol. 2006;8:903-911.
22. Caffo O, Fellin G, Graffer U, et al. Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer. Int J Radiat Oncol Biol Phys. 2003;57:1310-1316.
23. Fahmy NM, Mahmud S, Aprikian AG. Delay in the surgical treatment of bladder cancer and survival: systematic review of the literature. Eur Urol. 2006;50:1176-1182.
24. Zietman AL, Grocela J, Zehr E, et al. Selective bladder preservation using transurethral resection, chemotherapy and radiation: management and consequences of Ta, T1, and Tis recurrences within the retained bladder. Urology. 2001; 58:380-385.
25. Zietman AL, Sacco D, Skowronski U, et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol. 2003;170:1772-1776.
26. Given RW, Parsons JT, McCarley D, et al. Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: a 5-year follow up. Urology. 1995;46:499-504.
27. Rodel C, Weiss C, Sauer R. Organ preservation by combined modality treatment in bladder cancer: the European perspective. Semin Radiat Oncol. 2004;15:28-35.
28. Kim HL, Steinberg GD. The current status of bladder preservation in the treatment of muscle invasive bladder cancer. J Urol. 2000;164:627-632.